At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
In Brief
A Phase 3 clinical trial evaluating Capecitabine, Fluorouracil, and 4 other interventions for Colon Adenocarcinoma and Stage IIA Colon Cancer AJCC v8. Active but no longer recruiting, targeting 635 participants across 957 sites in 3 countries.
Detailed Summary
This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy.
Study Details
Timeline
Interventions
Given PO
Given IV
Given IV
Given IV
Give IV
Undergo active surveillance